Teladoc Health (NYSE:TDOC) Price Target Cut to $14.00 by Analysts at Evercore ISI

Teladoc Health (NYSE:TDOC) had its price objective reduced by Evercore ISI from $15.00 to $14.00 in a research note published on Friday morning, Benzinga reports. They currently have an in-line rating on the health services provider’s stock.

TDOC has been the subject of a number of other reports. Royal Bank of Canada reduced their price target on shares of Teladoc Health from $30.00 to $25.00 and set an outperform rating for the company in a research report on Wednesday, February 21st. Stifel Nicolaus reduced their price target on shares of Teladoc Health from $21.00 to $16.00 and set a hold rating for the company in a research report on Friday. DA Davidson reduced their price target on shares of Teladoc Health from $22.00 to $18.00 and set a neutral rating for the company in a research report on Wednesday, February 21st. Needham & Company LLC reaffirmed a hold rating on shares of Teladoc Health in a report on Friday. Finally, Cantor Fitzgerald began coverage on shares of Teladoc Health in a report on Thursday, February 29th. They issued an overweight rating and a $22.00 target price for the company. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Teladoc Health presently has an average rating of Hold and a consensus target price of $19.67.

Teladoc Health Price Performance

Teladoc Health stock opened at $13.01 on Friday. The company has a fifty day simple moving average of $15.01 and a 200-day simple moving average of $17.77. Teladoc Health has a 12-month low of $12.65 and a 12-month high of $30.41. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The company had revenue of $646.13 million during the quarter, compared to analysts’ expectations of $637.31 million. During the same period last year, the firm earned ($0.37) earnings per share. Teladoc Health’s revenue was up 2.7% on a year-over-year basis. Research analysts expect that Teladoc Health will post -1.07 EPS for the current year.

Insider Transactions at Teladoc Health

In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $19.18, for a total transaction of $151,176.76. Following the transaction, the insider now directly owns 57,223 shares in the company, valued at $1,097,537.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Teladoc Health news, CMO Stephany Verstraete sold 7,945 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $115,361.40. Following the transaction, the chief marketing officer now directly owns 56,486 shares in the company, valued at $820,176.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Laizer Kornwasser sold 7,882 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $19.18, for a total transaction of $151,176.76. Following the completion of the sale, the insider now directly owns 57,223 shares in the company, valued at approximately $1,097,537.14. The disclosure for this sale can be found here. Insiders have sold a total of 135,441 shares of company stock worth $2,038,251 over the last ninety days. 1.63% of the stock is currently owned by company insiders.

Institutional Trading of Teladoc Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Newbridge Financial Services Group Inc. lifted its holdings in shares of Teladoc Health by 2,130.9% in the first quarter. Newbridge Financial Services Group Inc. now owns 11,400 shares of the health services provider’s stock valued at $172,000 after purchasing an additional 10,889 shares in the last quarter. Westside Investment Management Inc. lifted its holdings in shares of Teladoc Health by 37.7% in the first quarter. Westside Investment Management Inc. now owns 5,662 shares of the health services provider’s stock valued at $85,000 after purchasing an additional 1,550 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Teladoc Health by 74.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 20,568 shares of the health services provider’s stock valued at $311,000 after purchasing an additional 8,750 shares in the last quarter. Counterpoint Mutual Funds LLC purchased a new stake in shares of Teladoc Health in the first quarter valued at about $271,000. Finally, Ignite Planners LLC lifted its holdings in shares of Teladoc Health by 6.9% in the first quarter. Ignite Planners LLC now owns 13,307 shares of the health services provider’s stock valued at $198,000 after purchasing an additional 857 shares in the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.